Charles Brenner, PhD

Charles Brenner, PhD

Creator
0 followers

Biochemist known for NAD+ biology; shares critical analyses of NR/NMN and metabolism studies.

Questioning Geroscience: Shingles Vaccine Shows Unexpected Effects
SocialApr 15, 2026

Questioning Geroscience: Shingles Vaccine Shows Unexpected Effects

i don’t believe there is an evidence basis for the value proposition of the geroscience hypothesis shingles vaccination was targeted to a specific virus yet this one intervention prevents Alzheimer’s disease and increases all cause mortality is the geroscience hypothesis...

By Charles Brenner, PhD
Discrepancy in Mouse Counts Raises Partial Reprogramming Concerns
SocialApr 13, 2026

Discrepancy in Mouse Counts Raises Partial Reprogramming Concerns

okay, tell me why you think browder et al had 21 mice in -dox and only 15 mice in the +dox group when they did partial reprogramming? https://t.co/gedJiKSRKo 6 more mice in the dox group got tummy aches and asked out of...

By Charles Brenner, PhD
OSK Reprogramming Triggers Tumors, Undermining Mouse Study Confidence
SocialApr 13, 2026

OSK Reprogramming Triggers Tumors, Undermining Mouse Study Confidence

OSK reprogramming also produces tumors see https://t.co/dNhcHVSBf3 cancer is a selective process clones grow out because they have a proliferative advantage or apoptotic disadvantage when mouse papers say no cancer despite the fact that half of lab mice die from cancer, i don't feel...

By Charles Brenner, PhD
IPSC Therapies Succeed; In‑vivo Reprogramming Remains Hype
SocialApr 12, 2026

IPSC Therapies Succeed; In‑vivo Reprogramming Remains Hype

your regular reminder that Yamanaka factor-driven production of iPSCs is already producing real medicine (eg dopaminergic neural progenitor for Parkinson's, cardiomyocyte sheets for heart failure & more) iPSC tech is not done in vivo... ppl isolate the well behaved cells away...

By Charles Brenner, PhD
Shingles Vaccine Beats Geroscience in Reducing Dementia
SocialApr 7, 2026

Shingles Vaccine Beats Geroscience in Reducing Dementia

a different take: the shingles vaccine lowers dementia and all cause mortality and it’s targeted to a specific virus, not the process of aging so far the data say the score is shingles vaccine 1, geroscience hypothesis 0 and I could say the...

By Charles Brenner, PhD
Targeting “Zombie” Cells Misguided for Healthy Aging
SocialMar 18, 2026

Targeting “Zombie” Cells Misguided for Healthy Aging

it was always dumb to talk about killing so called zombie cells in the context of healthy aging

By Charles Brenner, PhD
Exploring Known and Unknowns in NAD Coenzyme Research
SocialMar 17, 2026

Exploring Known and Unknowns in NAD Coenzyme Research

looking forward to concluding next week's NAD for Health conference in Copenhagen with a talk on Known Knowns and Known Unknowns in NAD Coenzyme Research.... see you there https://t.co/hLAnAq7Fay

By Charles Brenner, PhD
NR/NMN Lack Human Anti‑Aging Proof, Only PAD Benefits
SocialMar 8, 2026

NR/NMN Lack Human Anti‑Aging Proof, Only PAD Benefits

stated as a critique but what does this mean as no drug has been demonstrated to have anti-aging effects in human clinical trials NR is active versus inflammaging and PAD, which is an age-related conditions affecting 10s of millions of americans you...

By Charles Brenner, PhD
NR Kinase 2 Rises in NAD‑decline Diseases, May Boost Supplementation
SocialMar 7, 2026

NR Kinase 2 Rises in NAD‑decline Diseases, May Boost Supplementation

that’s a high level question MO the specific value of NR relates to the tissue distribution of NMRK1 and NMRK2 NR kinase 2 is strongly upregulated in conditions of NAD decline including heart failure and peripheral neurodegeneration

By Charles Brenner, PhD
NR Boosts NAD 2.3× More than NMN at 1.2 G/Day
SocialMar 6, 2026

NR Boosts NAD 2.3× More than NMN at 1.2 G/Day

ppl have been asking for head to head comparisons of NR v NMN in humans the data show that at 1.2 g/day, NR had 2.3x the blood NAD-boosting activity versus NMN the paper and the details in this 🧵 https://t.co/7KuP6LXyia

By Charles Brenner, PhD